Regeneron Pharmaceuticals, Inc. (REGN) Now Covered by Analysts at Royal Bank Of Canada
Stock analysts at Royal Bank Of Canada initiated coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. Canaccord Genuity set a $484.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, June 20th. BTIG Research reissued a “buy” rating and set a $540.00 target price (up from $480.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, June 30th. BidaskClub cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Bank of America Corporation reissued a “buy” rating and set a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Citigroup Inc. boosted their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $496.35.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.81% during trading on Thursday, hitting $441.30. The company had a trading volume of 873,444 shares. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The company’s 50 day moving average is $479.23 and its 200 day moving average is $445.02. The firm has a market capitalization of $46.79 billion, a P/E ratio of 44.27 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The business’s revenue was up 21.2% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last three months, insiders sold 120,690 shares of company stock worth $57,732,183. 10.40% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of REGN. Gabelli Funds LLC increased its position in Regeneron Pharmaceuticals by 13.3% in the first quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock worth $2,635,000 after buying an additional 800 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Regeneron Pharmaceuticals by 30.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,641 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 1,307 shares in the last quarter. TFS Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $480,000. Toronto Dominion Bank increased its position in Regeneron Pharmaceuticals by 57.4% in the first quarter. Toronto Dominion Bank now owns 20,540 shares of the biopharmaceutical company’s stock worth $7,958,000 after buying an additional 7,487 shares in the last quarter. Finally, NEXT Financial Group Inc increased its position in Regeneron Pharmaceuticals by 2.3% in the first quarter. NEXT Financial Group Inc now owns 916 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 21 shares in the last quarter. 67.96% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.